Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Related Donors
Phase II Study for Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplants From Matched Related Donors
Sponsor: Miltenyi Biotec, Inc.
A NA clinical study on Hematopoietic Stem Cell Transplantation, this trial is ongoing. The trial is conducted by Miltenyi Biotec, Inc. and has accumulated 17 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
17 versions recorded-
Jan 2026 — Present [monthly]
Active Not Recruiting NA
-
Jan 2025 — Jan 2026 [monthly]
Active Not Recruiting NA
-
Sep 2024 — Jan 2025 [monthly]
Active Not Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting NA
-
Jan 2024 — Jul 2024 [monthly]
Active Not Recruiting NA
▶ Show 12 earlier versions
-
Jan 2023 — Jan 2024 [monthly]
Active Not Recruiting NA
-
May 2022 — Jan 2023 [monthly]
Active Not Recruiting NA
-
Sep 2021 — May 2022 [monthly]
Active Not Recruiting NA
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting NA
-
Feb 2020 — Jan 2021 [monthly]
Active Not Recruiting NA
-
Jan 2020 — Feb 2020 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Feb 2019 — Jan 2020 [monthly]
Recruiting NA
-
Dec 2018 — Feb 2019 [monthly]
Recruiting NA
-
Jun 2018 — Dec 2018 [monthly]
Recruiting NA
-
Dec 2017 — Jun 2018 [monthly]
Recruiting NA
Phase: PHASE2 → NA
-
Feb 2017 — Dec 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Oct 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Miltenyi Biotec, Inc.
- University of Alabama at Birmingham
For direct contact, visit the study record on ClinicalTrials.gov .